Anticoagulation in hospitalized patients with COVID-19. Blood 2022 Aug 25;140(8):809-814
Date
06/03/2022Pubmed ID
35653590Pubmed Central ID
PMC9361053DOI
10.1182/blood.2021014527Scopus ID
2-s2.0-85136551504 (requires institutional sign-in at Scopus site) 13 CitationsAbstract
Coronavirus disease-19 (COVID-19) includes a thromboinflammatory syndrome that may manifest with microvascular and macrovascular thrombosis. Patients with COVID-19 have a higher incidence of venous thromboembolism than other hospitalized patients. Three randomized control trials suggesting benefit of therapeutic heparin in hospitalized noncritically ill patients with COVID-19 have led to conditional guideline recommendations for this treatment. By contrast, prophylactic-dose heparin is recommended for critically ill patients. Unprecedented collaboration and rapidly funded research have improved care of hospitalized patients with COVID-19.
Author List
Baumann Kreuziger L, Sholzberg M, Cushman MAuthor
Lisa M. Baumann Kreuziger MD Associate Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnticoagulantsBlood Coagulation
Heparin
Humans
Venous Thromboembolism